French pharma giant Sanofi will invest some 1 billion euros ($1.05 billion) to establish a new insulin production base in ...

Sanofi is one of the world's top producers of insulin, and the China market for treatment of the illness is huge: Some 140 ...

Sanofi’s latest capital outlay in China will cover the development of a new insulin plant in the nation’s capital.

JPMorgan raised the firm’s price target on Sanofi (SNY) to EUR 105 from EUR 100 and keeps a Neutral rating on the shares.Don't Miss our Black ...

Sanofi a leading global healthcare company invests ampeuro1 billion in Beijing for a new insulin plant creating jobs and bolstering China health ...

The "North America Orthobiologics Market Outlook to 2033 - Orthobiologics, Cartilage Repair and Others" report has been added to ResearchAndMarkets.com's offering.The North American orthobiologics ...

The divestiture of the Czech facility follows U.S.-based Novavax's licensing deal worth at least $1.2 billion with French ...

In 2024, domestic and foreign equity holders sold shares worth over $30 billion via block deals, showcasing sustained ...

IGM Biosciences has pivoted from cancer therapeutics to autoimmune diseases despite setbacks, showing a 25% stock increase since last October. Click for more on IGMS.

The Chinese government's policies promoting opening up and innovation, as well as the excellent business environment it fosters for foreign enterprises, have injected strong confidence into Sanofi's ...

Novavax sells manufacturing facility to Novo Nordisk for $200M, enabling Novavax to advance growth strategy and drive value ...